{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:13:28Z","timestamp":1792804408014,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jns.2017.12.035","type":"journal-article","created":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T11:46:18Z","timestamp":1514634378000},"page":"175-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["Autoimmune and paraneoplastic movement disorders: An update"],"prefix":"10.1016","volume":"385","author":[{"given":"Jos\u00e9 Fidel","family":"Baizabal-Carvallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2017.12.035_bb0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/imt-2017-0146","article-title":"Immunologic treatment of Parkinson's disease","volume":"10","author":"Jankovic","year":"2018","journal-title":"Immunotherapy"},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.12.035_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2013.02.007","article-title":"Movement disorders in multiple sclerosis and other demyelinating diseases","volume":"328","author":"Mehanna","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jns.2017.12.035_bb0015","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/mds.870120512","article-title":"Chorea in fifty consecutive patients with rheumatic fever","volume":"12","author":"Cardoso","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2017.12.035_bb0020","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.25011","article-title":"Movement disorders in autoimmune diseases","volume":"27","author":"Baizabal-Carvallo","year":"2012","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.jns.2017.12.035_bb0025","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/jnnp-2016-314475","article-title":"Autoimmune choreas","volume":"88","author":"Cardoso","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2017.12.035_bb0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1212\/WNL.59.2.227","article-title":"Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea","volume":"59","author":"Church","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.12.035_bb0035","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.4049\/jimmunol.178.11.7412","article-title":"Tubulin is a neuronal target of autoantibodies in Sydenham's chorea","volume":"178","author":"Kirvan","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2017.12.035_bb0040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/08830185.2014.917411","article-title":"Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection","volume":"33","author":"Cunningham","year":"2014","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.jns.2017.12.035_bb0045","series-title":"Streptococcus pyogenes: Basic Biology to Clinical Manifestations [Internet]","article-title":"Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)","author":"Orefici","year":"2016"},{"issue":"Pt 11","key":"10.1016\/j.jns.2017.12.035_bb0050","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/brain\/aws256","article-title":"Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders","volume":"135","author":"Dale","year":"2012","journal-title":"Brain"},{"issue":"Pt 1","key":"10.1016\/j.jns.2017.12.035_bb0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/brain\/awh008","article-title":"Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity","volume":"127","author":"Dale","year":"2004","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jns.2017.12.035_bb0060","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.25626","article-title":"N-methyl-d-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse","volume":"29","author":"Hacohen","year":"2014","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.jns.2017.12.035_bb0065","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ana.23689","article-title":"N-methyl-d-aspartate receptor antibodies in herpes simplex encephalitis","volume":"72","author":"Pr\u00fcss","year":"2012","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2017.12.035_bb0070","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ana.24083","article-title":"Herpes simplex virus encephalitis is a trigger of brain autoimmunity","volume":"75","author":"Armangue","year":"2014","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2017.12.035_bb0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mds.25623","article-title":"Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-methyl-d-aspartate receptor or dopamine-2 receptor","volume":"29","author":"Mohammad","year":"2014","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.jns.2017.12.035_bb0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2017.12.035_bb0085","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2017.12.035_bb0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ana.21756","article-title":"Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents","volume":"66","author":"Florance","year":"2009","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2017.12.035_bb0095","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/mds.25354","article-title":"The spectrum of movement disorders in children with anti-NMDAR encephalitis","volume":"28","author":"Baizabal-Carvallo","year":"2013","journal-title":"Mov. Disord."},{"issue":"37","key":"10.1016\/j.jns.2017.12.035_bb0100","doi-asserted-by":"crossref","first-page":"e 4365","DOI":"10.1097\/MD.0000000000004365","article-title":"Variations of movement disorders in anti-N-methyl-d-aspartate receptor encephalitis: A nationwide study in Taiwan","volume":"95","author":"Duan","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.jns.2017.12.035_bb0105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/mds.26093","article-title":"Myorhythmia: phenomenology, etiology, and treatment","volume":"30","author":"Baizabal-Carvallo","year":"2015","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.jns.2017.12.035_bb0110","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/mds.25999","article-title":"Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies","volume":"29","author":"Mohammad","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2017.12.035_bb0115","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Jankovic","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"issue":"5","key":"10.1016\/j.jns.2017.12.035_bb0120","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrneurol.2017.43","article-title":"The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis","volume":"13","author":"van Sonderen","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"18","key":"10.1016\/j.jns.2017.12.035_bb0125","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0000000000002637","article-title":"The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies","volume":"86","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2017.12.035_bb0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.24979","article-title":"Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG-positive patients","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2017.12.035_bb0135","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ana.22307","article-title":"Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis","volume":"69","author":"Irani","year":"2011","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2017.12.035_bb0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ana.23577","article-title":"Morvan syndrome: clinical and serological observations in 29 cases","volume":"72","author":"Irani","year":"2012","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2017.12.035_bb0145","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jamaneurol.2015.1715","article-title":"Clinical Spectrum of encephalitis associated with antibodies against the \u03b1-amino-3-Hydroxy-5-methyl-4-isoxazolepropionic acid receptor: case series and review of the literature","volume":"72","author":"Joubert","year":"2015","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.jns.2017.12.035_bb0150","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamaneurol.2013.4786","article-title":"Aggressive course in encephalitis with opsoclonus, ataxia, chorea, and seizures: the first pediatric case of \u03b3-aminobutyric acid type B receptor autoimmunity","volume":"71","author":"Kruer","year":"2014","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.jns.2017.12.035_bb0155","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/jnnp-2014-308814","article-title":"Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series","volume":"86","author":"Dogan Onugoren","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"17","key":"10.1016\/j.jns.2017.12.035_bb0160","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1212\/WNL.0b013e3182a9585f","article-title":"Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients","volume":"81","author":"H\u00f6ftberger","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2017.12.035_bb0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.jns.2017.12.035_bb0170","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1474-4422(13)70299-0","article-title":"Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies","volume":"13","author":"Petit-Pedrol","year":"2014","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.jns.2017.12.035_bb0175","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.0000000000003713","article-title":"Investigations in GABAA receptor antibody-associated encephalitis","volume":"88","author":"Spatola","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.12.035_bb0180","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/brain\/awu142","article-title":"Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes","volume":"137","author":"Carvajal-Gonz\u00e1lez","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.jns.2017.12.035_bb0185","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/jnnp.2010.229104","article-title":"Antiglycine-receptor encephalomyelitis with rigidity","volume":"82","author":"Mas","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"16","key":"10.1016\/j.jns.2017.12.035_bb0190","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1212\/01.wnl.0000327606.50322.f0","article-title":"Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody","volume":"71","author":"Hutchinson","year":"2008","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jns.2017.12.035_bb0195","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1007\/s00415-011-6078-x","article-title":"A case of glycine-receptor antibody-associated encephalomyelitis with rigidity and myoclonus (PERM): clinical course, treatment and CSF findings","volume":"258","author":"Piotrowicz","year":"2011","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2017.12.035_bb0200","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000339446","article-title":"Childhood stiff-person syndrome improved with rituximab","volume":"4","author":"Fekete","year":"2012","journal-title":"Case Rep. Neurol."},{"issue":"17","key":"10.1016\/j.jns.2017.12.035_bb0205","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1212\/WNL.0000000000000372","article-title":"Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies","volume":"82","author":"Balint","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2017.12.035_bb0210","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.23756","article-title":"Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels","volume":"73","author":"Boronat","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2017.12.035_bb0215","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000001907","article-title":"Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons","volume":"85","author":"Piepgras","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.12.035_bb0220","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2017.12.035_bb0225","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","article-title":"Clinical manifestations of the anti-IgLON5 disease","volume":"88","author":"Gaig","year":"2017","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2017.12.035_bb0230","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/jnnp-2014-309201","article-title":"Stiff-person syndrome: insights into a complex autoimmune disorder","volume":"86","author":"Baizabal-Carvallo","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2017.12.035_bb0235","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/jamaneurol.2016.0133","article-title":"Clinical and immunologic investigations in patients with stiff-person spectrum disorder","volume":"73","author":"Martinez-Hernandez","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2017.12.035_bb0240","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.expneurol.2013.02.010","article-title":"Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome","volume":"247","author":"Dalakas","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jns.2017.12.035_bb0245","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1212\/WNL.51.1.85","article-title":"Physiologic studies of spinal inhibitory circuits in patients with stiff-person syndrome","volume":"51","author":"Floeter","year":"1998","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2017.12.035_bb0250","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/jnnp.2003.018135","article-title":"Hyperekplexia and stiff-man syndrome: abnormal brainstem reflexes suggest a physiological relationship","volume":"75","author":"Khasani","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2017.12.035_bb0255","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/archneur.62.6.970","article-title":"Brain gamma-aminobutyric acid changes in stiff-person syndrome","volume":"62","author":"Levy","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2017.12.035_bb0260","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/brain\/123.11.2231","article-title":"Motor cortex excitability in stiff-person syndrome","volume":"123","author":"Sandbrink","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.jns.2017.12.035_bb0265","doi-asserted-by":"crossref","DOI":"10.1007\/s00702-017-1754-3","article-title":"Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review","author":"Baizabal-Carvallo","year":"2017","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"10.1016\/j.jns.2017.12.035_bb0270","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/jamaneurol.2014.1011","article-title":"Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy","volume":"71","author":"Ari\u00f1o","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2017.12.035_bb0275","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1136\/jnnp-2016-314863","article-title":"Causes of progressive cerebellar ataxia: prospective evaluation of 1500 patients","volume":"88","author":"Hadjivassiliou","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2017.12.035_bb0280","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/jnnp.72.5.560","article-title":"Gluten sensitivity as a neurological illness","volume":"72","author":"Hadjivassiliou","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2017.12.035_bb0285","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12311-015-0664-x","article-title":"Consensus paper: neuroimmune mechanisms of cerebellar ataxias","volume":"15","author":"Mitoma","year":"2016","journal-title":"Cerebellum"},{"issue":"11","key":"10.1016\/j.jns.2017.12.035_bb0290","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00702-013-1023-z","article-title":"Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome","volume":"120","author":"Baizabal-Carvallo","year":"2013","journal-title":"J. Neural. Transm. (Vienna)"},{"issue":"13","key":"10.1016\/j.jns.2017.12.035_bb0295","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/mds.23863","article-title":"Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies","volume":"26","author":"Reiner","year":"2011","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.jns.2017.12.035_bb0300","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.3899\/jrheum.080268","article-title":"Antiphospholipid antibody-associated chorea","volume":"35","author":"Orzechowski","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jns.2017.12.035_bb0305","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/RHU.0b013e31820e7c8d","article-title":"Chorea in systemic lupus erythematosus","volume":"17","author":"Baizabal-Carvallo","year":"2011","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.jns.2017.12.035_bb0310","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0091-6749(95)70268-7","article-title":"Antidopaminergic antibodies in a patient with a complex autoimmune disorder and rapidly progressing Parkinson's disease","volume":"96","author":"Kunas","year":"1995","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jns.2017.12.035_bb0315","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00415-006-0170-7","article-title":"The neurological disorder associated with thyroid autoimmunity","volume":"253","author":"Ferracci","year":"2006","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2017.12.035_bb0320","doi-asserted-by":"crossref","first-page":"156795","DOI":"10.1155\/2012\/156795","article-title":"\u03b1-Enolase, a multifunctional protein: its role on pathophysiological situations","volume":"2012","author":"D\u00edaz-Ramos","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"10.1016\/j.jns.2017.12.035_bb0325","first-page":"109","article-title":"Autoantibodies specific for alpha-enolase in systemic autoimmune disorders","volume":"27","author":"Pratesi","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jns.2017.12.035_bb0330","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/jnnp.2006.093005","article-title":"Hashimoto's encephalopathy presenting with progressive cerebellar ataxia","volume":"78","author":"Nakagawa","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.jns.2017.12.035_bb0335","doi-asserted-by":"crossref","first-page":"e 6181","DOI":"10.1097\/MD.0000000000006181","article-title":"Limbic encephalitis associated with anti-NH2-terminal of \u03b1-enolase antibodies: a clinical subtype of Hashimoto encephalopathy","volume":"96","author":"Kishitani","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.jns.2017.12.035_bb0340","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00023210-200721100-00002","article-title":"Hashimoto's encephalopathy: epidemiology, pathogenesis and management","volume":"21","author":"Mocellin","year":"2007","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.jns.2017.12.035_bb0345","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/archneurol.2012.1173","article-title":"Adult-onset opsoclonus-myoclonus syndrome","volume":"69","author":"Klaas","year":"2012","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2017.12.035_bb0350","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/jamaneurol.2015.4607","article-title":"Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies","volume":"73","author":"Armangu\u00e9","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2017.12.035_bb0355","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2017.12.035_bb0360","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2015.2378","article-title":"Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults","volume":"72","author":"Jones","year":"2015","journal-title":"JAMA Neurol."},{"issue":"Pt 8","key":"10.1016\/j.jns.2017.12.035_bb0365","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/brain\/awh203","article-title":"Clinical analysis of anti-Ma2-associated encephalitis","volume":"127","author":"Dalmau","year":"2004","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.jns.2017.12.035_bb0370","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1007\/s00415-011-6074-1","article-title":"Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience","volume":"258","author":"Vigliani","year":"2011","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2017.12.035_bb0375","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/jnnp.2007.138016","article-title":"Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2\/CRMP5 antibodies","volume":"80","author":"Honnorat","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2017.12.035_bb0380","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1212\/01.wnl.0000327342.58936.e0","article-title":"Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease","volume":"71","author":"Murinson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.12.035_bb0385","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/jnnp.73.3.345","article-title":"Acute attacks and brain stem signs in a patient with glutamic acid decarboxylase autoantibodies","volume":"73","author":"Matsumoto","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.jns.2017.12.035_bb0390","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1212\/WNL.0b013e3182886991","article-title":"Autoimmune chorea in adults","volume":"80","author":"O'Toole","year":"2013","journal-title":"Neurology"},{"issue":"166","key":"10.1016\/j.jns.2017.12.035_bb0395","article-title":"'Medusa-head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: anti-mGluR1, anti-Homer-3, anti-Sj\/ITPR1 and anti-CARP VIII","volume":"12","author":"Jarius","year":"2015","journal-title":"J. Neuroinflammation"},{"issue":"167","key":"10.1016\/j.jns.2017.12.035_bb0400","article-title":"'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: anti-PKC-gamma, anti-GluR-delta2, anti-Ca\/ARHGAP26 and anti-VGCC","volume":"12","author":"Jarius","year":"2015","journal-title":"J. Neuroinflammation"},{"issue":"168","key":"10.1016\/j.jns.2017.12.035_bb0405","article-title":"'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: anti-Yo\/CDR2, anti-Nb\/AP3B2, PCA-2, anti-Tr\/DNER, other antibodies, diagnostic pitfalls, summary and outlook","volume":"12","author":"Jarius","year":"2015","journal-title":"J. Neuroinflammation"},{"issue":"9","key":"10.1016\/j.jns.2017.12.035_bb0410","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/archneurol.2010.209","article-title":"Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri)","volume":"67","author":"Pittock","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2017.12.035_bb0415","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jns.2016.01.006","article-title":"Autoimmune atypical parkinsonism - a group of treatable parkinsonism","volume":"362","author":"Kannoth","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2017.12.035_bb0420","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ana.20693","article-title":"Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis","volume":"59","author":"Iranzo","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2017.12.035_bb0425","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neuroscience.2015.05.037","article-title":"Imaging of autoimmune encephalitis\u2014relevance for clinical practice and hippocampal function","volume":"309","author":"Heine","year":"2015","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/j.jns.2017.12.035_bb0430","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2967\/jnumed.116.184333","article-title":"Diagnostic value of 18F-FDG PET\/CT versus MRI in the setting of antibody-specific autoimmune encephalitis","volume":"58","author":"Solnes","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.jns.2017.12.035_bb0435","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/archneur.61.8.1261","article-title":"Recurrence of Sydenham chorea: implications for pathogenesis","volume":"61","author":"Korn-Lubetzki","year":"2004","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2017.12.035_bb0440","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.parkreldis.2005.02.007","article-title":"Treatment of acute Sydenham's chorea with methyl-prednisolone pulse-therapy","volume":"11","author":"Teixeira","year":"2005","journal-title":"Parkinsonism Relat. Disord."},{"issue":"4","key":"10.1016\/j.jns.2017.12.035_bb0445","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.pediatrneurol.2005.08.028","article-title":"Randomized double-blind study with prednisone in Sydenham's chorea","volume":"34","author":"Paz","year":"2006","journal-title":"Pediatr. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2017.12.035_bb0450","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejpn.2011.12.005","article-title":"Acute and chronic corticosteroid treatment of ten patients with paralytic form of Sydenham's chorea","volume":"16","author":"Fusco","year":"2012","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2017.12.035_bb0455","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13311-015-0410-6","article-title":"Antibody-mediated autoimmune encephalopathies and immunotherapies","volume":"13","author":"Gastaldi","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"26","key":"10.1016\/j.jns.2017.12.035_bb0460","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immune globulin for stiff-person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jns.2017.12.035_bb0465","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ana.25002","article-title":"A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome","volume":"82","author":"Dalakas","year":"2017","journal-title":"Ann. Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17345276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17345276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T06:54:25Z","timestamp":1530600865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17345276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":93,"alternative-id":["S0022510X17345276"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.12.035","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune and paraneoplastic movement disorders: An update","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}